AMPH:NASDAQ
Amphastar Pharmaceuticals, Inc
$29.37
arrow_upward
+1.73%(+0.50) 1D
Nov 13, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMPH...
Open
$29.05
High
$29.73
Low
$28.84
Mkt. cap
1.25B
Avg. vol.
454.84K
Volume
380.76K
P/E ratio
13.25
52-wk high
$30.79
52-wk low
$16.64
EPS
$2.22
Beta
0.93
Shares outstanding
42.65M
No. of employees
2K
Open
$29.05
High
$29.73
Low
$28.84
Mkt. cap
1.25B
Avg. vol.
454.84K
Volume
380.76K
P/E ratio
13.25
52-wk high
$30.79
52-wk low
$16.64
EPS
$2.22
Beta
0.93
Shares outstanding
42.65M
No. of employees
2K
News stories
From web sources and news partners
Yahoo Finance
·
1 day ago
Stock market today: Dow, S&P 500, Nasdaq futures edge higher after wholesale inflation grows, Nvidia stock rebounds
Nasdaq
·
1 day ago
Chartstopper: November 13, 2026
Bloomberg.com
·
8 hours ago
SpaceX’s S&P 500 Bid Gets New Life as Musk Pitches Tesla Merger
Profile
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
About Amphastar Pharmaceuticals, Inc
CEO-
Employees1.98K
Founded1996
HeadquartersRancho Cucamonga, California, United States
SectorHealth Care
IndustryPharmaceutical industry
Websiteamphastar.com